Opthea Limited logo

Opthea Limited

ASX:OPT.AX

Overview | Financials
Company Name Opthea Limited
Symbol OPT.AX
Currency AUD
Price 0.37
Market Cap 446,253,300
Dividend Yield 0%
52-week-range 0.313 - 0.815
Industry Biotechnology
Sector Healthcare
CEO Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D.
Website https://opthea.com

An error occurred while fetching data.

About Opthea Limited

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel

Related Stocks

Neuren Pharmaceuticals Limited logo

Neuren Pharmaceuticals Limited

NEU.AX

20.52 AUD

Monash IVF Group Limited logo

Monash IVF Group Limited

MVF.AX

1.3 AUD

AFT Pharmaceuticals Limited logo

AFT Pharmaceuticals Limited

AFP.AX

3.2 AUD

Sigma Healthcare Limited logo

Sigma Healthcare Limited

SIG.AX

1.295 AUD

Incannex Healthcare Limited logo

Incannex Healthcare Limited

IHL.AX

0.041 AUD

Mayne Pharma Group Limited logo

Mayne Pharma Group Limited

MYX.AX

4.4 AUD

Trajan Group Holdings Limited logo

Trajan Group Holdings Limited

TRJ.AX

1 AUD

Capitol Health Limited logo

Capitol Health Limited

CAJ.AX

0.295 AUD

Immutep Limited logo

Immutep Limited

IMM.AX

0.355 AUD

Financials

Numbers are in millions USD

Numbers are in millions USD